Vis børsmeldingen
today launched a new dedicated area on its website (www.nordicnanovector.com)
with information in Norwegian for shareholders relating to its proposed merger
with APIM Therapeutics (“APIM”).
The new area includes a recording of the webcast and Question & Answer session,
which was held for interested parties, including shareholders, on 24 November.
During the webcast, shareholders were provided with a more-detailed presentation
of the proposed merger with APIM and were given the opportunity to ask their
specific questions regarding the merger plans.
Malene Brondberg, Interim CEO and CFO of Nordic Nanovector, says: “We are happy
that so many shareholders attended the webcast we hosted yesterday, where we
provided more background on the proposed merger with APIM Therapeutics. After a
week of highly productive meetings between the Nordic Nanovector and APIM teams,
our confidence in a merged company is even stronger than before. Our largest
shareholder Folketrygdfondet confirms that it supports the Board’s proposal. We
are certain that there is no better alternative, and we encourage all
shareholders to vote in favour of the merger proposal.”
The proposed merger, which is backed by the Boards of Directors of both
companies, is the result of an extensive review conducted by Nordic Nanovector
in conjunction with Carnegie Investment Bank (“Carnegie”) that explored a range
of strategic options for the Company. This review included carefully evaluating
a potential stand-alone strategy for Nordic Nanovector, which was deemed not to
be a viable option by the Board.
After evaluating 25 possible merger and acquisition opportunities, the Company
determined that the merger transaction with APIM represents the best and most
exciting opportunity for all of Nordic Nanovector’s shareholders given, among
other things, the significant and broad potential of ATX-101, a novel anti
-cancer peptide currently in Phase 2 trials. In addition, the combined company
will have the discovery and development expertise to potentially generate
multiple value-enhancing new drug candidates from its technology platforms.
How to register for the general meeting
Shareholders wishing to attend the general meeting must register no later than
29 November 2022 at 16:00 hours (CET). Shareholders can attend in person, by
proxy or by casting advance votes. The deadline is the same for proxies and
advance votes as personal attendance. Until the deadline, votes already cast may
be changed or withdrawn.
Electronic registration of attendance, proxies and advance voting is easily
available through the link posted at the Company’s website:
www.nordicnanovector.com. An individual ref. no. and PIN-code required to access
the service have been sent to all shareholders with known address.
Registration of personal attendance and proxies can also be made by mail to
Nordea Bank Abp, Norwegian branch, Issuer Services, P.O. Box 1166 Sentrum, N
-0107 Oslo, Norway, or e-mail to: nis@nordea.com within the deadline. No ref.
no. and PIN-code is required for registration by mail or e-mail.
The form of registration of attendance (in person or by proxy) is attached with
the notice as made available on Nordic Nanovector’s website and on the company’s
ticker on newsweb.no
Advisers
Carnegie Investment Bank is acting as financial advisor to Nordic Nanovector.
Advokatfirmaet Selmer AS is acting as legal advisor to Nordic Nanovector and
KPMG AS assisted Nordic Nanovector with financial due diligence and a fairness
opinion of the exchange ratio.
Advokatfirmaet Schjødt AS is acting as legal advisor to APIM. The valuation of
APIM Therapeutics was conducted by Venture Valuation AG, which has now agreed to
be identified.
Contacts
Jan H. Egberts, Chairman of Nordic Nanovector
+31 614672518
janegberts@aol.com
Malene Brondberg, Interim CEO and CFO of Nordic Nanovector
ir@nordicnanovector.com
International Media - Frazer Hall / Mark Swallow (MEDiSTRAVA Consulting)
+44 203 928 6900
nordicnanovector@medistrava.com
Media in Norway - Stein Jacob Frisch (Lilleby Frisch)
+47 916 10 911
sjf@lillebyfrisch.no
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company’s pipeline includes:
· Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies
incorporating the beta emitter lutetium-177 to treat non-Hodgkin’s lymphoma
(NHL);
· Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the
alpha-emitting radionuclide lead-212, currently being explored with partner
Oranomed for chronic lymphocytic leukaemia;
· Multiple fully humanized anti-CD37 antibodies with potential in
haematological cancers and autoimmune diseases; and
· A CD37 DOTA CAR-T cell opportunity in haematological cancers, which is being
advanced via a research collaboration with the University of Pennsylvania.
Further information can be found at www.nordicnanovector.com.
Important information
This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities. The distribution of this
announcement and other information may be restricted by law in certain
jurisdictions. Copies of this announcement are not being made and may not be
distributed or sent into any jurisdiction in which such distribution would be
unlawful or would require registration or other measures. Persons into whose
possession this announcement or such other information should come are required
to inform themselves about and to observe any such restrictions.
Matters discussed in this announcement constitute forward-looking statements.
Forward-looking statements are statements that are not historical facts and may
be identified by words such as “believe”, “expect”, “anticipate”, “strategy”,
“intends”, “estimate”, “will”, “may”, “continue”, “should” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although Nordic Nanovector believes that these assumptions were reasonable when
made, these assumptions are inherently subject to significant known and unknown
risks, uncertainties, contingencies, and other important factors which are
difficult or impossible to predict and are beyond its control.
The information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without notice.
Nordic Nanovector undertakes no obligation to review, update, confirm, or to
release publicly any revisions to any forward-looking statements to reflect
events that occur or circumstances that arise in relation to the content of this
announcement.
This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities.
Kilde
